More on IPSEY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $46.50 |
|
|||
| Open | $46.50 | ||||
| 52 Wk High | $17.79 | ||||
| 52 Wk Low | $13.01 | ||||
| Day High | $46.50 | ||||
| Day Low | $46.50 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 417 | ||||
- National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare
- Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
- FDA: Alerts health care providers and patients about increased risk of new blood cancers with Tazverik (tazemetostat) use
- Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
- Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
- Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
- U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
- BNP Paribas Exane Downgrades Ipsen SA (IPN:FP) (IPSEY) to Underperform
- Ipsen presents long-term IQIRVO data at liver disease conference
- Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
Entities mentioned with IPSEY
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- Dividend | View Related Stories »
- Stock Buyback | View Related Stories »
- S1 | View Related Stories »
- Deutsche Bank | View Related Stories »
- Show More...
